Welcome to Arizona’s Bioscience Roadmap, a long-term strategic plan originally commissioned by the Flinn Foundation in 2002 and updated in 2014 with the goal of Arizona becoming globally competitive and a national leader in select areas of the biosciences by 2025.
2. Turning research into practice;
3. Developing bio-talent;
4. Promoting Arizona’s convergence of research, health care, and commercialization to economic partners in neighboring states, Canada, and Mexico; and
5. Enhancing the state’s “collaborative gene” reputation.
The Roadmap is guided by Arizona’s Bioscience Roadmap Steering Committee, a group of about 135 state leaders from the private and public sectors in science, health care, business, academia, and policy.
The Roadmap was compiled by the Battelle Technology Partnership Practice based on research and input from Arizona leaders as well as national bioscience experts. Battelle produced a comprehensive study released in 2002 that found Arizona possessed many of the essential elements needed to become a global leader in niche areas in the biosciences, but must strengthen its biomedical-research base and build a critical mass of bioscience firms and jobs.
The Flinn Foundation has commissioned Battelle, followed by TEConomy Partners, since the inception of Arizona’s Bioscience Roadmap to track progress on performance measures involving the state’s bioscience sector.
The data pertaining to a consistent set of metrics, including jobs, wages, capital, research and development, and technology transfer, is gathered and reported publicly on a biennial basis.
In addition, the Flinn Foundation tracks the progress of the bioscience sector each year by highlighting the state’s major developments.
In April 2021, the Flinn Foundation hosted its annual event to share the impressive progress of Arizona’s growing sector nearly two decades since the launch of Arizona’s Bioscience Roadmap.
The latest data, released in April 2020, can be found in this detailed analysis from TEConomy Partners, “Biosciences in Arizona: 2020 Performance Review.”